DNA Testing Mushroom Supplements: Species Identity

Mushroom Supplement Quality

93% of US reishi products were not G. lucidum

DNA barcoding of the ITS region can identify which Ganoderma, Hericium, or Phellinus-related species is actually in a supplement powder or extract. Loyd et al. 2018 used this method to test 20 US reishi products and found that 93% contained Ganoderma lingzhi rather than G. lucidum sensu stricto — a botanical-naming issue with real implications for what 'reishi' on a label means.

Loyd et al., Frontiers in Microbiology, 2018

ITS region

the standard fungal DNA barcode for species identification

Gunnels 2020

validated ITS-based identification across 7 commercial Ganoderma supplements (all G. lingzhi at 99.5–100% match)

Multi-method needed

DNA testing answers species identity but not potency; Windsor 2025 showed cereal-grain alpha-glucan dominates myceliated chaga products

Loyd et al., Frontiers in Microbiology, 2018

View as image ↗

Every mushroom supplement bottle tells you what species it contains. DNA testing can now verify whether the label is telling the truth.

DNA barcoding reads a short, highly variable section of an organism's genetic code to determine exactly what species it comes from. For mushroom supplements, the target is the ITS region — the internal transcribed spacer — a stretch of non-coding DNA between ribosomal gene sequences. The ITS region varies significantly between species but stays consistent within a species. Any ground mushroom powder, extract, or raw ingredient can be amplified via PCR and matched against sequences in genetic databases, providing a direct answer: is this Ganoderma lucidum, or is it a different Ganoderma species? Is this Hericium erinaceus, or something else entirely?

The reason this matters: species substitution and mislabeling are documented problems in the mushroom supplement market. Research published in both the US and internationally has found that a significant proportion of commercial mushroom supplements do not contain the species their labels claim. Understanding how DNA testing works — and what the science has established — is the first step toward knowing which quality markers to look for when buying.

For the regulatory context that explains why species mislabeling persists, see How the FDA Regulates Mushroom Supplements: The DSHEA Framework.

What ITS DNA Barcoding Is and How It Identifies Mushrooms

Every species of organism has a unique genetic code. Within that code, certain short regions are particularly useful for identification purposes: they're consistent within a species (so you know you've got a match) but different enough between species that you can tell them apart reliably.

For fungi, the ITS region is the gold standard for species identification. ITS stands for internal transcribed spacer. It's a short stretch of DNA between the genes that encode the components of ribosomes (the cell's protein-making machinery). Because this region serves no protein-coding function, it accumulates mutations freely over evolutionary time, which is why it varies so much between species. But within a species, it stays remarkably stable — a Lion's Mane mushroom from Japan and one from Canada have essentially identical ITS sequences.

The practical process for testing a supplement works as follows. A small amount of the powder or extract is taken. DNA is extracted from it using standard molecular biology techniques. The ITS region is then amplified using a method called PCR — polymerase chain reaction — which makes millions of copies of just that one target sequence. The amplified sequence is then read using a sequencer and compared against reference databases (GenBank and others contain tens of thousands of verified fungal ITS sequences). If the supplement contains Hericium erinaceus, the ITS sequence from the product will match the reference sequence for H. erinaceus. If it contains a different species, the mismatch is unambiguous.

Gunnels and colleagues validated this approach specifically for reishi (Ganoderma) supplements in a 2020 paper published in PLoS ONE.^[1] Their work demonstrated that the ITS region provides a reliable barcode for distinguishing different Ganoderma species in herbal supplements — including processed and extracted forms where intact mushroom tissue is no longer present. This is significant because supplement powders and extracts are heavily processed; the ITS-based approach is robust enough to work even after the physical structure of the mushroom has been destroyed.

What Research Found When DNA Testing Was Applied to Commercial Products

The technology has been used to audit the market, and the results reveal a genuine problem.

Loyd and colleagues, writing in Frontiers in Microbiology in 2018, examined the species composition of 20 manufactured reishi products and 17 grow-your-own kits sold in the United States.^[2] Their DNA-based analysis (ITS plus tef1α sequencing, with Illumina MiSeq for mixtures) found that 93% of the manufactured reishi products were identified as Ganoderma lingzhi — the species native to Asia and the most widely cultivated taxon for medicinal use. None of the manufactured products contained G. lucidum sensu stricto, which has a limited native distribution in Europe and parts of China.

This is more nuanced than a simple "fraud" story. For most of the modern medicinal-mushroom literature, "G. lucidum" was used loosely for laccate Asian Ganoderma material, which is now known to be largely G. lingzhi. The naming gap reflects taxonomy catching up with biology rather than supplement companies substituting unrelated mushrooms. That said, Loyd and colleagues also detected several other Ganoderma species in the tested products — G. applanatum, G. australe, G. gibbosum, G. sessile, and G. sinense — and these species have different compound profiles and different (or absent) research bases. They concluded that better labeling is needed before products are ingested or marketed as medicine.

The taxonomic-naming issue is not unique to Ganoderma.

Han and colleagues, working in Korea in 2016, conducted a phylogenetic analysis of 74 strains in the Phellinus linteus–baumii complex based on ITS nrDNA sequences.^[3] The major sanghuang strains formally registered with the Korea Seed & Variety Service — including Corea sanghuang (ASI 26046), Boolro (26114), and HK 1-ho (26115) — grouped phylogenetically with Sanghuangporus sanghuang rather than with P. linteus. This is a taxonomic re-assignment of the cultivated breeding strains, not a survey of commercial supplement labels. It is relevant because the species name "Phellinus linteus" continues to appear on supplement and pharmacology literature for material that is more properly identified as Sanghuangporus sanghuang.

What both studies show is that "the species on the label" can be ambiguous even before any commercial fraud is involved, because mushroom taxonomy is still being revised and product labels often lag the current names. For a fuller picture of how widespread adulteration is across the mushroom supplement market, see Mushroom Supplement Adulteration: How Widespread Is the Problem?

Why Species Substitution Happens

Species substitution in commercial supplements happens for several reasons, most of them economic rather than malicious.

Within the genus Ganoderma, for example, dozens of species exist worldwide and many are superficially similar in appearance to G. lucidum. Suppliers sourcing mushrooms internationally may receive alternate species that are visually indistinguishable without laboratory testing. The cost of routine identity verification has historically been prohibitive for smaller brands.

A different driver is the broader mycelium-on-grain supply chain. When mushroom supplements are produced from fermented mycelium (the root-like network of the fungus) grown on rice or grain, the resulting material looks similar regardless of which fungal species was cultured. Without DNA verification of the original culture identity and purity checks throughout production, the wrong species or a contaminating strain can silently end up in finished products.

Regulatory pressure is also limited. Under the DSHEA framework in the United States, supplement manufacturers are responsible for ensuring their products are accurately labeled, but pre-market verification is not required. The FDA enforces against egregious violations but does not have the resources to test all products on the market. For a detailed look at what regulatory enforcement actually catches, see FDA Warning Letters to Mushroom Companies: What Gets Flagged.

DNA Testing Alone Is Not Enough: The Multi-Method Standard

Windsor and colleagues published a 2025 comparative study of chaga supplements using multiple analytical techniques in parallel — HPTLC (high-performance thin-layer chromatography), LC-MS, NMR spectroscopy, UV-Vis, and ion-staining methods.^[4] Authentic wildcrafted chaga canker showed a low-alpha, moderate-beta glucan profile, while myceliated grain products flipped to high alpha-glucan content that tracked cereal starch. Lugol staining and alpha-amylase digestion confirmed that the alpha-glucan signal in myceliated products was starch-driven, not fungal. This is a clean demonstration of why a single "polysaccharide" number on a label is not enough.

This is an important limitation of DNA testing: it answers the species identity question but cannot answer the potency question. A supplement can contain authentic Lion's Mane DNA while delivering essentially no biologically active compounds, either because the extraction was inefficient, the starting material was low quality, or the material was diluted with filler. Species identity and compound concentration are separate quality dimensions.

For reliable quality assurance, both are needed:

• DNA testing (ITS barcoding) confirms the species on the label is the species in the capsule
• Beta-glucan assay (the enzymatic (1,3)/(1,6)-beta-glucan method) confirms that mushroom-specific bioactive compounds are present at meaningful concentrations, not just starch from grain filler

Neither alone is sufficient. A product that passes DNA testing could still be low-potency. A product that reports high polysaccharide content could still contain the wrong species (or count starch as polysaccharides, which the incorrect test method does). For a detailed breakdown of the starch and polysaccharide labeling problem, see Starch Filler in Mushroom Supplements: The Dirty Secret.

Asking for DNA-Verified Species Identity

For most of the history of DNA barcoding in supplements, ITS-based species testing was confined to academic research. A company or consumer who wanted DNA identity testing for a mushroom product would have needed to commission custom molecular biology work from a university or specialist lab — expensive and time-consuming.

That has begun to change as commercial testing laboratories have started to offer ITS-based species identification for botanical and fungal supplement ingredients. Brands willing to invest in that testing can now provide DNA-verified species identity claims as part of a Certificate of Analysis, which is a meaningfully higher standard than the supplier-attestation labels that have historically dominated the category. Consumers who care about species identity can ask whether a brand's raw material has been DNA-verified at the ITS level, and whether the supporting test report is available on request.

A brand that can provide an ITS-sequencing-based COA is providing independent species verification. A brand that cannot may be relying entirely on supplier attestation. Specific commercial offerings change frequently and are best confirmed directly with the testing laboratory and the supplement manufacturer.

What Consumers Should Ask For

Translating the research into practical buying criteria:

Ask for a Certificate of Analysis that includes DNA species verification. Not all COAs are equal. A COA that lists "polysaccharide content" without specifying the test method used for species identification is not providing DNA-verified identity. A COA that specifically references ITS sequencing or an equivalent molecular barcode method is.

Understand that species labeling and potency labeling are separate. "Certified as Ganoderma lingzhi by DNA testing" and "contains 30% beta-glucans" are two different claims that require two different tests. A complete quality picture includes both.

Be skeptical of COAs that only report "total polysaccharides." Standard polysaccharide assays can count alpha-glucan (grain starch) as polysaccharides. Without a specific enzymatic (1,3)/(1,6)-beta-glucan assay that excludes alpha-glucan, a high polysaccharide number can be carried entirely by cereal starch — exactly the pattern Windsor 2025 found in myceliated chaga grain products. For a practical guide to reading supplement labels and COAs, see How to Spot Adulterated Mushroom Products.

The combination of ITS-based species verification (Gunnels 2020, Loyd 2018) and a real beta-glucan assay (Windsor 2025) is what gives a quality picture that consumers can actually act on. Either alone leaves a gap.

The Bottom Line

ITS DNA barcoding is a validated method for identifying fungal species in supplement powders and extracts. Loyd et al. 2018 found that 93% of US manufactured "reishi" products were Ganoderma lingzhi rather than G. lucidum sensu stricto (a botanical-naming issue, with some products also containing other Ganoderma species), and Gunnels et al. 2020 validated the ITS method on commercial Ganoderma material. Han et al. 2016 reclassified the major Korean sanghuang breeding strains from Phellinus linteus to Sanghuangporus sanghuang. DNA testing verifies species identity but cannot confirm compound potency — Windsor et al. 2025 showed that myceliated chaga grain products are dominated by cereal-starch alpha-glucan, so a complete quality picture requires both ITS-based species verification and an enzymatic (1,3)/(1,6)-beta-glucan assay.

Frequently Asked Questions

Can you DNA test a mushroom supplement?

Yes. ITS (internal transcribed spacer) DNA barcoding can identify the species present in a mushroom supplement powder or extract, even after processing. The DNA is extracted from the product, the ITS region is amplified via PCR, sequenced, and matched against reference databases. Commercial testing laboratories increasingly offer ITS-based species identification for botanical and fungal supplement ingredients; specific service offerings change over time and are best confirmed directly with the testing laboratory and the supplement manufacturer.

How accurate is DNA testing for identifying mushroom species?

Highly accurate for species identity. The ITS region varies enough between fungal species that misidentifications are uncommon when using validated reference databases. Gunnels et al. (2020) validated ITS barcoding specifically for Ganoderma (reishi) supplements and confirmed it reliably identifies species and detects substitution. The limitation is scope: DNA testing confirms species identity but cannot measure the concentration of active compounds like beta-glucans or cordycepin.

What labs offer DNA testing for mushroom supplements?

Major commercial testing laboratories offer ITS-based species identification for botanical and fungal supplement ingredients, and brands can request this testing for their raw materials. The specific labs and species covered change over time, so the most current list is best confirmed directly with the testing laboratory or the supplement manufacturer's COA.

What is ITS DNA barcoding for mushrooms?

ITS (internal transcribed spacer) barcoding is a molecular identification method that reads a short, highly variable section of fungal DNA located between ribosomal gene sequences. Because this region varies significantly between species but stays consistent within a species, it acts as a reliable genetic fingerprint. In practice: take a small amount of supplement powder, extract the DNA, amplify the ITS region via PCR, sequence it, and compare it to reference databases — the result tells you exactly which species of mushroom the sample contains.

Why do mushroom supplements contain the wrong species?

Species substitution in mushroom supplements most often occurs through supply chain failures rather than intentional fraud. Suppliers sourcing internationally may receive similar-looking species that are difficult to distinguish visually. Brands that rely on supplier documentation rather than independent testing have limited ability to catch substitution. Under DSHEA, the FDA does not require pre-market verification of species identity. Economically, testing has historically been expensive and not required, making it easy to skip. DNA testing is the most direct way to close this verification gap.

Sources & References

1. 1RTHM-00615·Gunnels, Tess et al. (2020). “The ITS region provides a reliable DNA barcode for identifying reishi/lingzhi (Ganoderma) from herbal supplements..” PloS one.Study breakdown →PubMed →↩
2. 2RTHM-00981·Loyd, Andrew L et al. (2018). “Identifying the "Mushroom of Immortality": Assessing the Ganoderma Species Composition in Commercial Reishi Products..” Frontiers in microbiology.Study breakdown →PubMed →↩
3. 3RTHM-00783·Han, Jae-Gu et al. (2016). “Species identity of Phellinus linteus (sanghuang) extensively used as a medicinal mushroom in Korea..” Journal of microbiology (Seoul.Study breakdown →PubMed →↩
4. 4RTHM-02209·Windsor, Coleton et al. (2025). “What This 2025 Chaga Supplement Authentication Study Actually Found.” International journal of molecular sciences.Study breakdown →PubMed →↩